Scholarlink

Introduction <p>Using the ATN framework, we evaluated the potential of plasma biomarkers to identify abnormal brain amyloid-beta (Aβ) positron emission tomography (PET), tau-PET and neurodegeneration in a socioeconomically disadvantaged population-based cohort.</p> Methods <p>Community-dwelling dementia-free (<i>n</i> = 113, including 102 (91%) cognitively normal) participants underwent ATN neuroimaging and plasma biomarker assessments.</p> Results <p>Plasma Aβ42/Aβ40, p-tau181, and p-tau217 showed significant associations with Aβ-PET status, (adjusted odds ratio [AOR] of 1.74*10<sup>–24</sup>, 1.47, and 3.43*10<sup>3</sup>, respectively (<i>p</i>-values &lt; 0.05), with p-tau217 demonstrating the highest classification accuracy for Aβ-PET status (AUC = 0.94). Plasma p-tau181 and p-tau217 showed significant associations with tau-PET status (AOR: 1.50 and 22.24, respectively (<i>p</i>-values &lt; 0.05), with comparable classification accuracies for tau-PET status (AUC = 0.74 and 0.70, respectively). Only plasma NfL showed significant association with neurodegeneration based on cortical thickness (AOR = 1.09, <i>p</i>-value &lt; 0.05).</p> Conclusion <p>Our findings highlight the potential of plasma p-tau217 as a biomarker for brain Aβ and tau pathophysiology, p-tau181 for tau abnormalities, and NfL for neurodegeneration in the community.</p>

错误：搜索内容不能为空，请输入英文关键词
错误：关键词超出字数限制，请精简
高级检索

Plasma biomarkers identify brain ATN abnormalities in a dementia-free population-based cohort

  • 期刊论文

  • 出版模式：

    开放获取

  • 发表日期：

    2025年7月25日

查看全文
  • Menayit Tamrat Dresse,
  • Pamela C. L. Ferreira,
  • Akshay Prasadan,
  • Jihui L. Diaz,
  • Xuemei Zeng,
  • Bruna Bellaver,
  • Guilherme Povala,
  • Victor L. Villemagne,
  • M. Ilyas Kamboh,
  • Ann D. Cohen,
  • Tharick A. Pascoal,
  • Mary Ganguli,
  • Beth E. Snitz,
  • C. Elizabeth Shaaban,
  • Thomas K. Karikari

摘要

Introduction

Using the ATN framework, we evaluated the potential of plasma biomarkers to identify abnormal brain amyloid-beta (Aβ) positron emission tomography (PET), tau-PET and neurodegeneration in a socioeconomically disadvantaged population-based cohort.

Methods

Community-dwelling dementia-free (n = 113, including 102 (91%) cognitively normal) participants underwent ATN neuroimaging and plasma biomarker assessments.

Results

Plasma Aβ42/Aβ40, p-tau181, and p-tau217 showed significant associations with Aβ-PET status, (adjusted odds ratio [AOR] of 1.74*10–24, 1.47, and 3.43*103, respectively (p-values < 0.05), with p-tau217 demonstrating the highest classification accuracy for Aβ-PET status (AUC = 0.94). Plasma p-tau181 and p-tau217 showed significant associations with tau-PET status (AOR: 1.50 and 22.24, respectively (p-values < 0.05), with comparable classification accuracies for tau-PET status (AUC = 0.74 and 0.70, respectively). Only plasma NfL showed significant association with neurodegeneration based on cortical thickness (AOR = 1.09, p-value < 0.05).

Conclusion

Our findings highlight the potential of plasma p-tau217 as a biomarker for brain Aβ and tau pathophysiology, p-tau181 for tau abnormalities, and NfL for neurodegeneration in the community.